This site is intended for healthcare professionals
Latest drug news
  • Home
  • /
  • News
  • /
  • 2011
  • /
  • 11
  • /
  • CHMP recommends Nevanac(Alcon/Novartis) for Diabet...
Drug news

CHMP recommends Nevanac(Alcon/Novartis) for Diabetic Macular Oedema following Cataract Surgery

Read time: 1 mins
Last updated:21st Nov 2011
Published:21st Nov 2011
Source: Pharmawand
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion on a new indication for Nevanac (nepafenac), from Alcon/Novartis, as follows: "Reduction in the risk of postoperative macular oedema associated with cataract surgery in diabetic patients". Cystoid macular edema (CME) can occur following routine, uncomplicated cataract surgery. Because macular oedema is sometimes refractory to therapy, prevention is clearly desirable. Several studies have suggested that routine use of NSAID drops , such as Nevanac may prevent macular edema. A large study by Wolf et. al supported this approach and demonstrated that prophylaxis with the topical NSAID nepafenac plus a corticosteroid is more effective than a corticosteroid alone.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.